myriamed supports local soccer club

myriamed supports local soccer club

myriamed supports the local soccer club SV Puma with a small donation to help them buy new sportswear. We hope that the COVID-19 pandemic will be over soon and team sports can take place again.

About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.

myriamed gives access to the following expertise:

• high quality human iPSC-derived somatic cells (myrCell) to be used in drug discovery and development.

• macroscale (3D) tissue (myrTissue) generated from the respective iPSC lines with properties of postnatal tissue for advanced screening and target validation.

• A highly parallelized phenotypic screening service (myrScreen).

myriamed has therefore two main types of activities, the generation of high-quality biological material allowing the research of new therapeutic targets, and the realization of customized phenotypic screenings.

About SV Puma: SV Puma Goettingen was founded in 1973 and is located in Göttingen in Germany. In both men's and women's soccer, the club offers bundled expert knowledge and playing soccer in a pleasant atmosphere with a colorful mix of students, trainees and professionals. The women's team currently plays in the district league. The two men's teams currently play in the 2nd and 3rd district class.

To learn more about SV Puma please visit: https://bit.ly/Puma_eV

myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.

The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.

At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.

This article was published on openPR.

Go back

Copyright 2021 Seaside Media. All Rights Reserved.